

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/067114 A1

(51) International Patent Classification:

C07D 205/04 (2006.01) C07D 213/74 (2006.01)
C07D 207/09 (2006.01) C07D 213/75 (2006.01)
C07D 207/27 (2006.01) C07D 213/85 (2006.01)
C07D 211/26 (2006.01) C07D 221/20 (2006.01)
C07C 235/54 (2006.01) C07D 231/12 (2006.01)
A61P 25/28 (2006.01) C07D 233/32 (2006.01)
C07D 211/38 (2006.01) C07D 233/70 (2006.01)
C07D 211/54 (2006.01)

(21) International Application Number:

PCT/US2021/052074

(22) International Filing Date:

24 September 2021 (24.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/083,685 25 September 2020 (25.09.2020) US

(71) Applicant: **NEUROPORE THERAPIES, INC.** [US/US];
10835 ROAD TO THE CURE, SUITE 230, SAN DIEGO,
California 92121 (US).

(72) Inventors: **NATALA, Srinivasa Reddy**; c/o Neuropore
Therapies, Inc., 10835 Road to the Cure, Suite 230, San
Diego, California 92121 (US). **WRASIDLO, Wolfgang J.**;
c/o Neuropore Therapies, Inc., 10835 Road to the Cure,
Suite 230, San Diego, California 92121 (US). **STOCKING,**
Emily M.; c/o Neuropore Therapies, Inc., 10835 Road to
the Cure, Suite 230, San Diego, California 92121 (US).

(74) Agent: **DO, Keunbong** et al.; Morrison & Foerster LLP,
425 Market Street, San Francisco, 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING



(57) Abstract: The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

WO 2022/067114 A1